{"id":171232,"date":"2025-09-15T05:31:49","date_gmt":"2025-09-15T09:31:49","guid":{"rendered":"https:\/\/44.250.171.167\/?p=171232"},"modified":"2025-09-15T05:31:49","modified_gmt":"2025-09-15T09:31:49","slug":"dr-reddy-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-reddy-q1-fy26-earnings-results\/","title":{"rendered":"Dr Reddy Q1 FY26 Earnings Results"},"content":{"rendered":"<h2><strong>Company Overview:<\/strong><\/h2>\n<p>Dr. Reddy&#8217;s Laboratories Ltd is a prominent Indian pharmaceutical company offering a broad range of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations.<\/p>\n<h2><strong>Financial Highlights for Q1 FY26:<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b98,572 crore, up 11.38% year-on-year from \u20b97,696 crore<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b96,957 crore, up 15.81% year-on-year from \u20b96,007 crore<\/li>\n<li><strong>Consolidated Net Profit:<\/strong> \u20b91,410 crore, up 1.29% year-on-year from \u20b91,392 crore<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b916.99, up 1.80% year-on-year from \u20b916.69<\/li>\n<\/ul>\n<h2><strong>Performance Insights:<\/strong><\/h2>\n<ul>\n<li>Revenues increased by over 11% with sustained growth across key domestic and international markets.<\/li>\n<li>Expenses rose about 16%, led by higher raw material, R&amp;D, and operating costs, compressing margins.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/12e5364f-0652-4c3c-afc0-088141ba5f14.pdf\" target=\"_blank\" rel=\"noopener\">Net profit<\/a> inched up by 1% as top-line growth was largely offset by cost escalation.<\/li>\n<li>The company maintains a strong presence in APIs, generics, and biosimilars, with continued investments in complex formulations.<\/li>\n<li><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-171233\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png\" alt=\"DRREDDY 1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/li>\n<\/ul>\n<h2><strong>Outlook:<\/strong><\/h2>\n<p>Dr. Reddy\u2019s Laboratories aims to drive further growth by expanding its global footprint, developing differentiated products, and pursuing operational efficiencies in FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/drreddy\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Overview: Dr. Reddy&#8217;s Laboratories Ltd is a prominent Indian pharmaceutical company offering a broad range of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Financial Highlights for Q1 FY26: Revenue: \u20b98,572 crore, up 11.38% year-on-year from \u20b97,696 crore Total Expenses: \u20b96,957 crore, up 15.81% year-on-year [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":171233,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[1115],"class_list":["post-171232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":171232,"position":0},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171315,"url":"https:\/\/alphastreet.com\/india\/emcure-q1-fy26-earnings-results-2\/","url_meta":{"origin":171232,"position":1},"title":"Emcure Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 17, 2025","format":false,"excerpt":"Company Overview: Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally, serving diverse therapeutic segments. Presenting below its Q1 FY26 Earnings Results. Financial Highlights for Q1 FY26: Revenue: \u20b92,101 crore, up 15.76% year-on-year from \u20b91,815 crore Total Expenses: \u20b91,810 crore, up 10.91% year-on-year from \u20b91,632 crore Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"EMCURE Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":171232,"position":2},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170447,"url":"https:\/\/alphastreet.com\/india\/aarti-drugs-q1-fy26-earnings-results\/","url_meta":{"origin":171232,"position":3},"title":"Aarti Drugs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Drugs Ltd, established in 1984 and part of the $1000 million Aarti Group of Industries, is engaged in manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, as well as pharmaceutical formulations. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9591 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIDRUGS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170383,"url":"https:\/\/alphastreet.com\/india\/gmm-pfaudler-q1-fy26-earnings-results\/","url_meta":{"origin":171232,"position":4},"title":"GMM Pfaudler Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 20, 2025","format":false,"excerpt":"GMM Pfaudler Ltd manufactures corrosion-resistant glass-lined equipment and is a leading supplier of process equipment to the pharmaceutical and chemical industries. The company has diversified its offerings to include mixing systems, filtration & drying equipment, engineered systems, and heavy engineering equipment. Presenting below are its Q1 FY26 Earnings Results Q1\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"GMMPFAUDLER Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GMM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GMM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GMM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GMM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GMM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GMM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171070,"url":"https:\/\/alphastreet.com\/india\/concord-biotech-q1-fy26-earnings-results\/","url_meta":{"origin":171232,"position":5},"title":"Concord Biotech Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 9, 2025","format":false,"excerpt":"Concord Biotech Limited, incorporated in 1984, is an India-based R&D-driven biopharma company specializing in the manufacture of fermentation-based active pharmaceutical ingredients (APIs) primarily for immunosuppressants and oncology. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results: Revenue: \u20b9204 crore, down 5.56% year-on-year YoY from \u20b9216 crore Total Expenses:\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"CONCORDBIO Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/171232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=171232"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/171232\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/171233"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=171232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=171232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=171232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}